Patient Characteristics (n = 74)
| Characteristic | Value |
| Median age (y) | 61 (range, 28–82) |
| Sex | |
| Male | 53 (71.6) |
| Female | 21 (28.4) |
| Histologic type | |
| Adenocarcinoma | 59 (79.7) |
| Poorly cohesive carcinoma | 15 (20.3) |
| Differentiation (n = 59) | |
| Well to moderate | 33 (55.9) |
| Poor | 26 (44.1) |
| HER2 status | |
| Negative | 60 (81.1) |
| Positive | 14 (18.9) |
| Having primary lesion of the stomach | |
| No | 15 (20.3) |
| Yes | 59* (79.7) |
| ECOG PS | |
| 0, 1 | 65 (87.8) |
| 2, 3 | 9 (12.2) |
| Chemotherapy regimen | |
| FOLFOX | 31 (41.9) |
| XELOX | 23 (31.1) |
| XP+H | 14 (18.9) |
| Other | 6 (8.1) |
| Median PFS (mo) | 8.0 (95% CI, 6.61–9.33) |
| Response rate (%) | 41 |
| Disease control rate (%) | 70 |
| Median overall survival (mo) | 17.4 (95% CI, 12.15–22.65) |
↵* Number of undetected lesions in baseline PET was 3, and of reproducibly measurable lesions on CT scan it was 4.
ECOG PS = Eastern Cooperative Oncology Group Performance Status; FOLFOX = fluorouracil with leucovorin and oxaliplatin; XELOX = capecitabine and oxaliplatin; XP+H = capecitabine and cisplatin and trastuzumab.
Data in parentheses are percentages, unless otherwise indicated.